Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Medicine"
DOI: 10.1080/07853890.2022.2045347
Abstract: Abstract Background: Previous studies have proven that Purinostat Mesylate (PM) is a new HDAC inhibitor and exhibits significant antitumor efficacy. However, the clinical application of PM was greatly limited by its poor solubility in water… read more here.
Keywords: purinostat mesylate; solubility; spectroscopy; efficacy ... See more keywords